A new endoscopic ultrasonography image processing method to evaluate the prognosis for pancreatic cancer treated with interstitial brachytherapy

Table 1 The change in the fuzzy classification result and clinical parameters after brachytherapy in 25 unresectable pancreatic cancer patients

No.	FCS before brachytherapy	FCS after brachytherapy	FCS1	Tumor volume1	CA19912	Survival time (d)
1	22.30	80.40	-260.50%	-93%	-53%	58
2	16.30	33.52	-105.60%	14%	69%	69
3	70.60	88.61	-25.50%	42%	75%	50
4	50.30	60.24	-19.80%	53%	0%	80
5	52.60	56.80	-8.00%	2%	0%	53
6	60.30	63.50	-5.30%	0%	8%	67
7	87.52	90.31	-3.20%	0%	66%	198
8	88.50	90.20	-1.90%	-320%	17%	54
9	83.10	83.68	-0.70%	0%	NA	103
10	90.80	91.20	-0.40%	12%	0%	125
11	88.20	87.20	1.10%	-15%	NA	200
12	90.20	88.93	1.40%	-171%	0%	143
13	91.30	88.70	2.80%	0%	0%	138
14	92.43	89.20	3.50%	48%	0%	221
15	95.10	88.20	7.30%	-1%	6%	312
16	89.21	80.12	10.20%	-104%	-30%	108
17	93.70	81.10	13.40%	71%	85%	61
18	87.52	75.21	14.10%	44%	-265%	182
19	92.20	61.23	33.60%	96%	0%	122
20	82.30	47.60	42.20%	78%	-3%	200
21	78.56	44.00	44.00%	-66%	-1%	150
22	75.90	35.62	53.10%	42%	13%	104
23	51.20	18.30	64.30%	40%	-358%	151
24	90.10	22.70	74.80%	61%	96%	194
25	89.30	18.64	79.10%	4%	95%	378
Groups
Increase (n = 10) (interquartile range)			-6.7% (43.9%)	1% (44%)	8% (68%)	67 (49)3
Decrease (n = 15) (interquartile range)			14.1% (49.6%)	40% (76%)	0% (41%)	151 (78)3

¹The parameter change was calculated by (pre-post)/pre;

²When the levels of carbohydrate antigen 199 (CA199) were larger than 1000 μmol/L before and after treatment, 0% meant no improvement;

³P = 0.001. FCS: Fuzzy classification score; NA: Not available.